Y-mabs announces positive naxitamab frontline data

Y-mabs announces positive naxitamab frontline data.y-mabs announces positive naxitamab frontline data.y-mabs therapeutics, inc - naxitamab treatment was well-tolerated.y-mabs therapeutics, inc - expects data from naxitamab study to be published in first half of 2020.y-mabs therapeutics, inc - also planning a multicenter frontline study, which co expects to initiate in 2020.
YMAB Ratings Summary
YMAB Quant Ranking